Safety and efficacy of tipranavir co-administered with low-dose ritonavir in patients with advanced HIV-1 infection and limited treatment options
2008
Methods Data from the German open-label study (EAP). To be included in the study, adult patients (pts) had to be triple antiretroviral (ARV) class experienced having failed at least two previous PI-based regimens. TPV/r 500/200 mg, twice daily, was added to a background regimen chosen by the treating physician. All adverse events (AE) were reported regardless of causal relationship and degree of seriousness.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI